
Please try another search
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Bernard Coulie | 59 | 2016 | President, CEO & Director |
John T. Curnutte | 74 | 2017 | Independent Director |
Darren S. Cline | 61 | 2023 | Independent Director |
Hoyoung Huh | 56 | 2017 | Independent Chairman & Lead Director |
Suzanne L. Bruhn | 62 | 2016 | Independent Director |
Gayle A. Crowell | 74 | 2019 | Independent Director |
Steve Edward Krognes | 57 | 2024 | Independent Director |
Rik Derynck | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Dean Sheppard | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
Hal Chapman | - | 2015 | Scientific Founder & Member of Scientific Advisory Board |
David R. Phillips | - | - | Member of Scientific Advisory Board |
Bertus Eksteen | - | - | Member of Scientific Advisory Board |
Naftali Kaminski | - | - | Member of Scientific Advisory Board |
Brian W. Metcalf | 79 | - | Member of Scientific Advisory Board |
David E. I. Pyott | 72 | 2021 | Independent Director |
Bill Greenlee | - | - | Member of Scientific Advisory Board |
Paul W. Noble | - | - | Member of Scientific Advisory Board |
Katharine Knobil | 61 | 2022 | Independent Director |
Thomas A. McCourt | 68 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review